Thiogenesis Therapeutics, Corp. (TSXV:TTI)

Canada flag Canada · Delayed Price · Currency is CAD
0.7700
-0.0200 (-2.53%)
Aug 11, 2025, 4:00 PM EDT
-2.53%
Market Cap45.89M
Revenue (ttm)n/a
Net Income (ttm)-3.85M
Shares Out57.37M
EPS (ttm)-0.08
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,000
Average Volume38,653
Open0.7700
Previous Close0.7900
Day's Range0.7700 - 0.7700
52-Week Range0.5100 - 0.8800
Beta0.82
RSI44.59
Earnings DateAug 22, 2025

About Thiogenesis Therapeutics

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Patrice Rioux
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol TTI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.